Founded in 2013 across two sites, Leiden in the Netherlands and Gaithersburg in Maryland, the business now runs four offices spanning the Netherlands, the United States and Japan with a team of more than 80. The OrganoPlate was the first mass-produced, quality-controlled organ-on-a-chip platform, and the wider product range extends to OrganoReady, OrganoTEER and OrganoAccess. Tissue models combine perfused vasculature, connective tissue, immune components and epithelia, with named systems for liver, gut, kidney, lung, the blood-brain barrier and the nervous system. Studies fall into oncology, immunology, metabolic disease and ADME/toxicity, and can be run in a customer's own laboratory or handed to the in-house CRO team, with training offered to groups adopting the plates themselves. Machine learning analytics support interpretation of the multiplexed readouts, and more than 130 peer-reviewed papers and 200 completed projects have drawn on the technology.
MIMETAS
MIMETAS is a pioneer and global leader in organ-on-a-chip technology, developing predictive, human-derived 3D tissue models for drug discovery and development. Their proprietary OrganoPlate® platform enables high-throughput, physiologically relevant screening of compounds under continuous perfusion, significantly reducing reliance on animal testing while enhancing preclinical translational accuracy.
